Enanta Pharmaceuticals Stock Probability Of Bankruptcy

ENTA Stock

USD 6.28 0.42 7.17%

Enanta Pharmaceuticals' chance of distress is under 39% at this time. It has slight odds of undergoing some form of financial hardship in the near future. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Enanta balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Enanta Pharmaceuticals Piotroski F Score and Enanta Pharmaceuticals Altman Z Score analysis.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

The current year's Market Cap is expected to grow to about 212 M. The current year's Enterprise Value is expected to grow to about 203.6 M

Enanta Pharmaceuticals Company chance of distress Analysis

Enanta Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Enanta Pharmaceuticals Probability Of Bankruptcy

Less than 39%

Most of Enanta Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enanta Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Enanta Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Enanta Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Enanta Pharmaceuticals financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Earnings Share

(5.48)

Revenue Per Share

3.407

Quarterly Revenue Growth

(0.05)

Return On Assets

(0.17)

The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Capital Surpluse	Long Term Investments	Short Long Term Debt	Short Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.84	-0.53	0.31	0.8	0.72	0.96	0.17	0.98	0.76	0.54	0.89	0.87	0.94	0.69	-0.04	0.93	0.82	0.86	0.37	0.77	0.36
Total Stockholder Equity	0.84		-0.71	0.72	0.64	0.75	0.79	-0.39	0.8	0.66	0.09	0.58	0.55	0.79	0.3	0.31	0.73	0.73	0.59	0.67	0.45	-0.11
Net Debt	-0.53	-0.71		-0.76	-0.21	-0.58	-0.49	0.42	-0.55	-0.29	0.29	-0.2	-0.21	-0.43	0.01	-0.36	-0.44	-0.53	-0.34	-0.6	-0.19	0.47
Retained Earnings	0.31	0.72	-0.76		0.12	0.51	0.28	-0.79	0.29	0.15	-0.58	-0.02	-0.05	0.33	-0.34	0.61	0.21	0.39	0.06	0.84	-0.06	-0.7
Accounts Payable	0.8	0.64	-0.21	0.12		0.63	0.69	0.2	0.74	0.55	0.54	0.85	0.84	0.84	0.78	0.13	0.82	0.76	0.86	0.3	0.68	0.54
Net Receivables	0.72	0.75	-0.58	0.51	0.63		0.65	-0.15	0.72	0.43	0.19	0.61	0.61	0.67	0.41	0.21	0.66	0.85	0.7	0.53	0.44	-0.07
Short Term Investments	0.96	0.79	-0.49	0.28	0.69	0.65		0.2	0.99	0.72	0.53	0.86	0.82	0.91	0.65	-0.22	0.86	0.79	0.81	0.34	0.81	0.34
Total Liab	0.17	-0.39	0.42	-0.79	0.2	-0.15	0.2		0.2	0.09	0.77	0.46	0.49	0.18	0.6	-0.63	0.23	0.07	0.37	-0.57	0.5	0.8
Total Current Assets	0.98	0.8	-0.55	0.29	0.74	0.72	0.99	0.2		0.71	0.54	0.89	0.87	0.93	0.69	-0.17	0.89	0.85	0.87	0.37	0.82	0.34
Common Stock	0.76	0.66	-0.29	0.15	0.55	0.43	0.72	0.09	0.71		0.48	0.62	0.57	0.61	0.52	-0.07	0.67	0.44	0.54	0.09	0.46	0.34
Property Plant Equipment	0.54	0.09	0.29	-0.58	0.54	0.19	0.53	0.77	0.54	0.48		0.77	0.77	0.49	0.85	-0.57	0.59	0.33	0.64	-0.39	0.63	0.87
Current Deferred Revenue	0.89	0.58	-0.2	-0.02	0.85	0.61	0.86	0.46	0.89	0.62	0.77		0.98	0.91	0.82	-0.29	0.86	0.8	0.91	0.2	0.86	0.63
Long Term Debt	0.87	0.55	-0.21	-0.05	0.84	0.61	0.82	0.49	0.87	0.57	0.77	0.98		0.89	0.83	-0.27	0.85	0.82	0.95	0.21	0.88	0.64
Net Tangible Assets	0.94	0.79	-0.43	0.33	0.84	0.67	0.91	0.18	0.93	0.61	0.49	0.91	0.89		0.64	-0.02	0.89	0.86	0.86	0.5	0.83	0.38
Capital Surpluse	0.69	0.3	0.01	-0.34	0.78	0.41	0.65	0.6	0.69	0.52	0.85	0.82	0.83	0.64		-0.35	0.77	0.56	0.86	-0.19	0.73	0.82
Long Term Investments	-0.04	0.31	-0.36	0.61	0.13	0.21	-0.22	-0.63	-0.17	-0.07	-0.57	-0.29	-0.27	-0.02	-0.35		-0.04	0.03	-0.19	0.5	-0.45	-0.55
Short Long Term Debt	0.93	0.73	-0.44	0.21	0.82	0.66	0.86	0.23	0.89	0.67	0.59	0.86	0.85	0.89	0.77	-0.04		0.71	0.88	0.2	0.71	0.46
Short Term Debt	0.82	0.73	-0.53	0.39	0.76	0.85	0.79	0.07	0.85	0.44	0.33	0.8	0.82	0.86	0.56	0.03	0.71		0.86	0.63	0.77	0.19
Long Term Debt Total	0.86	0.59	-0.34	0.06	0.86	0.7	0.81	0.37	0.87	0.54	0.64	0.91	0.95	0.86	0.86	-0.19	0.88	0.86		0.24	0.87	0.57
Net Invested Capital	0.37	0.67	-0.6	0.84	0.3	0.53	0.34	-0.57	0.37	0.09	-0.39	0.2	0.21	0.5	-0.19	0.5	0.2	0.63	0.24		0.22	-0.48
Net Working Capital	0.77	0.45	-0.19	-0.06	0.68	0.44	0.81	0.5	0.82	0.46	0.63	0.86	0.88	0.83	0.73	-0.45	0.71	0.77	0.87	0.22		0.63
Capital Stock	0.36	-0.11	0.47	-0.7	0.54	-0.07	0.34	0.8	0.34	0.34	0.87	0.63	0.64	0.38	0.82	-0.55	0.46	0.19	0.57	-0.48	0.63

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	0.0947	(0.0744)	(0.18)	(0.32)	(0.29)	(0.31)
Asset Turnover	0.42	0.25	0.22	0.23	0.17	0.18
Net Debt	(79.0M)	(51.9M)	(18.7M)	(58.9M)	18.2M	19.1M
Total Current Liabilities	24.2M	36.2M	29.8M	62.8M	57.5M	60.4M
Non Current Liabilities Total	6.4M	3.2M	24.2M	182.8M	190.3M	199.8M
Total Assets	486.1M	438.8M	375.4M	462.3M	376.7M	333.8M
Total Current Assets	436.8M	319.0M	311.7M	422.8M	299.9M	274.9M
Total Cash From Operating Activities	7.1M	(70.0M)	(84.8M)	(103.2M)	(78.8M)	(74.8M)

	Return On Equity	-0.6
	Return On Asset	-0.17
	Profit Margin	(1.60) %
	Operating Margin	(1.35) %
	Current Valuation	(58.98 M)
	Shares Outstanding	21.19 M
	Shares Owned By Insiders	6.00 %
	Shares Owned By Institutions	94.00 %
	Number Of Shares Shorted	3.23 M
	Price To Earning	366.13 X
	Price To Book	1.04 X
	Price To Sales	1.85 X
	Revenue	67.64 M
	Gross Profit	86.16 M
	EBITDA	(104.51 M)
	Net Income	(116.05 M)
	Cash And Equivalents	253.29 M
	Cash Per Share	12.22 X
	Total Debt	55.47 M
	Debt To Equity	0.08 %
	Current Ratio	13.59 X
	Book Value Per Share	7.03 X
	Cash Flow From Operations	(78.76 M)
	Short Ratio	20.91 X
	Earnings Per Share	(5.48) X
	Target Price	16.88
	Number Of Employees	145
	Beta	0.57
	Market Capitalization	133.1 M
	Total Asset	376.65 M
	Retained Earnings	(323.04 M)
	Working Capital	360 M
	Current Asset	241.79 M
	Current Liabilities	9.57 M
	Net Asset	376.65 M

Enanta Pharmaceuticals Stock Probability Of Bankruptcy

Enanta Pharmaceuticals Company chance of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Enanta Pharmaceuticals Probability Of Bankruptcy

Enanta Probability Of Bankruptcy Driver Correlations

Enanta Probability Of Bankruptcy Peer Comparison

Enanta Pharmaceuticals Main Bankruptcy Drivers

Enanta Pharmaceuticals ESG Sustainability

Enanta Fundamentals

About Enanta Pharmaceuticals Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY